Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | MARK3 | P27448 | 2/20 | 0.34 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F12 | P00748 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355216 | 0.85 | CYP19A1 (0.38) | PIK3CDBTKCYP19A1 | |
| SCHEMBL3589889 | 0.82 | OPRL1 (0.34) | — | |
| SCHEMBL3590539 | 0.80 | PIK3CD (0.40) | PIK3CDBTKATRHSD11B1CTSD | |
| SCHEMBL1355225 | 0.77 | AURKA (0.41) | — | |
| SCHEMBL3585565 | 0.77 | MARK3 (0.42) | PIK3CDMARK3MARK4HTR6 | |
| SCHEMBL3587338 | 0.77 | MARK3 (0.42) | PIK3CDMARK3MARK4HTR6 | |
| SCHEMBL3576056 | 0.77 | MARK3 (0.42) | PIK3CDMARK3MARK4HTR6 | |
| SCHEMBL1356827 | 0.73 | HTR6 (0.39) | PIK3CDHTR6 | |
| SCHEMBL1356829 | 0.73 | HTR6 (0.39) | PIK3CDHTR6 | |
| SCHEMBL1356138 | 0.73 | KDM4E (0.38) | PIK3CDBTKATRHSD11B1MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | PIK3CD 347/4885BTK 794/4885ATR 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.